A significant development has emerged from the ACCENT pancreatic cancer clinical trial sponsored by Amplia Therapeutics in collaboration with Professor Paul Timpson at the Garvan Institute of Medical Research, two patients have achieved a pathological complete...

Researchers at the Garvan institute have published findings revealing a promising new therapeutic target to slow down or inhibit metastasis in pancreatic cancer. The study identified a metabolic signaling molecule involved in facilitating the spread of the disease to...

Prof Paul Timpson, head of the Invasion and Metastasis Lab, Professor Thomas Cox and Dr Brooke Pereira of the Garvan Institute of Medical Research were awarded funding from the Cancer Council to continue research into advancing treatment options for pancreatic cancer....